- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06373289
폐고혈압이 있는 영아의 목표 산소 범위 (PHOX)
기관지폐 이형성증 관련 폐고혈압이 있는 영아의 목표 산소 포화도 범위
Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.
연구 개요
상태
상세 설명
Infants born between 22.0 to 31.6 weeks' gestational age with bronchopulmonary dysplasia associated pulmonary hypertension, are receiving supplemental oxygen, and have mature retinas will be randomized to SpO2 targets of either (1) 92-95% (control) or (2) 95-98% (intervention).
Using a cross over design with a 1:1 parallel allocation of infants randomized using a stratified permuted block design. Following 1week of exposure A, infants will cross over to exposure B for 1 week with a 1-week washout period. Bedside providers will follow pre-specified algorithms to maintain oxygen targets during the randomization period. Reports of oxygen saturation performance will also be provided to bedside providers through oxygen saturation histograms.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Samuel Gentle, MD
- 전화번호: 205-541-2247
- 이메일: samjgentle@gmail.com
연구 연락처 백업
- 이름: Colm Travers
- 이메일: samuel.gentle@yale.edu
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 모병
- The University of Alabama at Birmingham
-
연락하다:
- Colm Travers
- 전화번호: 205-934-4011
- 이메일: cptravers@uabmc.edu
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- 모병
- Yale New Haven Hospital
-
연락하다:
- Samuel Gentle
- 전화번호: 205-541-2247
- 이메일: samuel.gentle@yale.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Between 22w 0/7d and 31w 6/7d gestation at birth
- Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
- Receiving supplemental oxygen
- Have mature retinas
Exclusion Criteria:
- Major congenital anomalies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Oxygen saturation target 92-95%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed to a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the lower oxygen saturation target. |
|
활성 비교기: Oxygen saturation target 95-98%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the higher oxygen saturation target. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Intermittent hypoxemia event duration
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
The average duration of time (in seconds) an infant's oxygen saturation decrease below 80%. |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Echocardiographic shunting
기간: through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
>20% flow of blood across the PDA from the pulmonary to arterial circulation |
through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic interventricular septal flattening
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
End-systolic flattening of the interventricular septum (eccentricity index >1.3) |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic tricuspid regurgitation
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Right ventricular pressure estimates |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Intermittent hypoxemia frequency
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Number of daily events during which an infant's oxygen saturation decreases below 80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Cumulative hypoxemia
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Daily duration during which an infant's oxygen saturation is <80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Brain natriuretic peptide
기간: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
A polypeptide released from the cardiac ventricles indicative of right heart strain |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Samuel Gentle, Yale University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 000539476
- 1K23HD113837-01A1 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .